In vitro susceptibility of staphylococci and enterococci to vancomycin and teicoplanin

Advances in Experimental Medicine and Biology

Volumn 788, Issue , 2013, Pages 125-132

  Guzek, A ^a   Korzeniewski, K ^a   Nitsch Osuch, Aneta ^b,c   Rybicki, Z ^a   Prokop, E ^c  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c St Family Maternity Hospital   (Poland)

Author keywords

Enterococci; Staphylococci; Susceptibility; Teicoplanin; Vancomycin

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STRAIN DIFFERENCE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 84881083637     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-6627-3_19     Document Type: Article

References (21)

1. Cetinkaya, Y., Falk, P., & Mayhall, C. (2000). Vancomycin-resistant enterococci. Clinical Microbiology Reviews, 19, 816-822.
2. Courvalin, P. (2006). Vancomycin resistance in grampositive cocci. Clinical Infectious Diseases, 42, S25-S34.
3. Cui, L., Ma, K., Sato, M., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M. N., Ploy, M. C., El-Solh, N., Ferraz, V., & Hiramatsu, K. (2003). Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. Journal of Clinical Microbiology, 41, 5-14. (Pubitemid 36098547)
4. Cui, L., Iwamoto, J., Neoh, H., Mruyama, T., Horikawa, Y., & Hiramatsu, K. (2006). Novel mechanisms of antibiotic resistance originating in vancomycinintermediate Staphylococcus aureus. Antimicrobial Agents Chemotherapy, 50, 428-438. (Pubitemid 43190949)
5. Hall, R., Giuliano, C., Haase, K., Hazelwood, K., Frei, C., Forcade, N., Brouse, S., Bell, T., Bedimo, R., & Alvarez, C. (2012). Empiric guide-line-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study. BMC Infectious Diseases, 12, 104-124.
6. Hryniewicz, W. (Ed.). (2000). Contemporary views on resistance of bacteria to antibiotics. Infections in intensive care-the place and role of antibiotics (pp. 1-15). Wroclaw: Urban & Partner (in Polish).
7. Hussain, F., Boyle-Vavra, P., Shete, B., & Daum, R. (2002). Evidence for continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. Journal of Infectious Diseases, 186, 661-667. (Pubitemid 34925538)
8. Jain, A., & Agarwal, A. (2009). Biofilm production, a marker of pathogenic potential of colonizing and commensal staphylococci. Journal of Microbiological Methods, 76, 88-92.
9. Jones, R. N. (2010). Microbial etiologies of hospitalacquired bacterial pneumonia and ventilatorassociated bacterial pneumonia. Clinical Infectious Diseases, 51(Suppl 1), S81-S87.
10. Joukhadar, C. (2001). Impaired target site penetration of b-lactams may account for therapeutic failure in patients with septic shock. Critical Care Medicine, 31, 2102-2109.
11. Kalil, A. C., Murthy, M. H., Hermsen, E. D., Neto, F. K., Sun, J., & Rupp, M. E. (2010). Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis. Critical Care Medicine, 38, 1802-1808.
12. Lodise, T., Grawes, A., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B., & Stellrecht, K. (2008). Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrobial Agents and Chemotherapy, 52, 3315-3320.
13. Ma, X., Wang, E., Liu, Y., & Luo, E. (2011). Antibiotic susceptibility of coagulase-negative staphylococci (CoNS): Emergence of teicoplanin-non-susceptible CoNS strains with inducible resistance to vancomycin. Journal of Medical Microbiology, 60, 1661-1668.
14. Mimoz, O., Rolland, D., Adoun, M., Marchand, S., Breilh, D., Brumpt, I., Debaene, B., & Couet, W. (2006). Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Medicine, 32, 775-779.
15. Nimmo, G., Pearson, J., Collignon, P., Christiansen, K., Coombs, G., Bell, J., & McLaws, M. (2011). Australian group on antimicrobial resistance. Communicable Diseases Intelligence, 35(3), 237-243.
16. Piette, A., & Verschragen, G. (2009). Role of coagulasenegative staphylococci in human disease. Veterinary Microbiology, 134, 45-54.
17. Pitz, A., Yu, E., Hermsen, E., Rupp, M., Fey, P., & Olsen, M. (2011). Vancomycin susceptibility and prevalence of heterogeneous vancomycin- intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. Journal of Clinical Microbiology, 49(1), 269-274.
18. Rybak, M., Leonard, S., Rosii, C., Cheung, C., Sader, H., & Jones, R. (2008). Characterization of vancomycinhetero resistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). Journal of Clinical Microbiology, 46, 2950-2954.
19. Smuszkiewicz, P., Szalek, E., Tomczak, H., Trojanowska, I., & Baszyk, M. (2007). Pharmacokinetic and pharmacodynamic use of antibiotics in patients treated for sepsis. Anaesthesiology Intensive Therapy, 3, 166-174 (in Polish).
20. Thierfelder, C., Keller, P., Kocher, C., Gaudenz, R., Hombach, M., Bloemberg, G., & Ruef, C. (2012). Vancomycin-resistant Enterococcus. A multi-strain outbreak of eight weeks duration at a Swiss tertiary care hospital. Swiss Medical Weekly, 5, 1-6.
21. Wisplinghof, H., Bischoff, T., Tallent, S., Seifert, H., Wenzel, R., & Edmond, M. (2004). Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective national wide surveillance study. Clinical Infectious Diseases, 39, 309-317. (Pubitemid 39050477)